AstraZeneca PLC (AZN), an International healthcare company, said Monday the U.S. Court of Appeals for the Federal Circuit has affirmed the summary judgment decision of no inequitable conduct in patent litigation involving Seroquel (quetiapine fumarate) tablets.

MAIN FACTS:

-Most recent decision upholds the District Court's judgment that Teva Pharmaceutical Industries Ltd.'s (TEVA)and Sandoz's products will infringe AstraZeneca's Seroquel patent and that the patent is valid and enforceable.

-AstraZeneca had sued Teva Pharmaceutical and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of abbreviated new drug applications.

-The patent covering Seroquel expires in September 2011, with paediatric exclusivity through March 2012.

-Since Federal Circuit Court of Appeals' affirmed Summary Judgment in favor of AstraZeneca, trial remains unnecessary.

 
-By London Bureau, Dow Jones Newswires; Contact Ian Walker; +44 (0)20 7842 9296; ian.walker@dowjones.com 
 
 
 
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Astrazeneca Charts.